Evidence map›Paper›PMID 42643875›Full record

ArticleMolecular therapy. Advances2026

RNA-TITER-An ADAR-based transcript detection assay for accelerated functional titer assessment of adeno-associated viruses.

Tanja Rothgangl, Nancy Carullo, Philip Ohland, Sandra Kemptner, Denis Phichith, Gianluigi Lichinchi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tanja RothganglTherapeutic Modalities, Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., 4058 Basel, Switzerland.
Nancy CarulloTherapeutic Modalities, Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., 4058 Basel, Switzerland.
Philip OhlandRoche Pharma Technical Development Cell and Gene Therapy, F. Hoffmann-La Roche Ltd., 4058 Basel, Switzerland.
Sandra KemptnerTherapeutic Modalities, Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., 4058 Basel, Switzerland.
Denis PhichithTherapeutic Modalities, Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., 4058 Basel, Switzerland.
Gianluigi LichinchiTherapeutic Modalities, Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., 4058 Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In gene therapy, payload design is a critical process that often requires the comparison of multiple vector architectures. However, current analytical pipelines for assessing transgene expression are time intensive, labor heavy, and costly. Here, we describe an RNA editing-based titratable indirect transgene expression reporter (RNA-TITER), an

Indexed as

AAVadeno-associated virusfunctional titergene therapypotency assayRADARrelease assayreprogrammable ADARRNA editingtransgene expression

Identifiers

PMID42643875
PMCPMC13505488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.